A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

NCT07725796 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder (Urothelial, Transitional Cell) Cancer
NMIBC
Urothelial Carcinoma Bladder
Urothelial Carcinoma in Situ
Urothelial Carcinoma Recurrent
Urothelial Carcinoma of the Urinary Bladder
Non-Muscle Invasive Bladder Carcinoma
Non-muscle Invasive Bladder Cancer (NMIBC)

Interventions

BIOLOGICAL: UGN-501

Sponsor

UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.